Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial

INTRODUCTION: Once-weekly (OW) subcutaneous (s.c.) semaglutide is an injectable glucagon-like peptide-1 (GLP-1) analogue approved for the treatment of type 2 diabetes. This trial was designed to assess the pharmacokinetics, safety and tolerability of OW s.c. semaglutide in healthy Chinese subjects....

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Aixin, Xie, Panpan, Nielsen, Lasse Lykke, Skjøth, Trine Vang, He, Xuemei, Haugaard, Sine Pfeiffer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854449/
https://www.ncbi.nlm.nih.gov/pubmed/33159658
http://dx.doi.org/10.1007/s12325-020-01548-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854449/
https://www.ncbi.nlm.nih.gov/pubmed/33159658
http://dx.doi.org/10.1007/s12325-020-01548-y

Ejemplares similares